These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

183 related articles for article (PubMed ID: 31591662)

  • 1. Influenza A(H5N1) Virus Subunit Vaccine Administered with CaPNP Adjuvant Induce High Virus Neutralization Antibody Titers in Mice.
    Morcol T; Nagappan P; Bell SJD; Cawthon AG
    AAPS PharmSciTech; 2019 Oct; 20(8):315. PubMed ID: 31591662
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Calcium phosphate nanoparticle (CaPNP) for dose-sparing of inactivated whole virus pandemic influenza A (H1N1) 2009 vaccine in mice.
    Morçӧl T; Hurst BL; Tarbet EB
    Vaccine; 2017 Aug; 35(35 Pt B):4569-4577. PubMed ID: 28716554
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Protective immunity against influenza H5N1 virus challenge in mice by intranasal co-administration of baculovirus surface-displayed HA and recombinant CTB as an adjuvant.
    Prabakaran M; Velumani S; He F; Karuppannan AK; Geng GY; Yin LK; Kwang J
    Virology; 2008 Oct; 380(2):412-20. PubMed ID: 18786689
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The Madin-Darby canine kidney cell culture derived influenza A/H5N1 vaccine: a phase I trial in Taiwan.
    Pan SC; Kung HC; Kao TM; Wu H; Dong SX; Hu MH; Chou AH; Chong P; Hsieh SM; Chang SC
    J Microbiol Immunol Infect; 2013 Dec; 46(6):448-55. PubMed ID: 23022464
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Priming with AS03 A-adjuvanted H5N1 influenza vaccine improves the kinetics, magnitude and durability of the immune response after a heterologous booster vaccination: an open non-randomised extension of a double-blind randomised primary study.
    Leroux-Roels I; Roman F; Forgus S; Maes C; De Boever F; Dramé M; Gillard P; van der Most R; Van Mechelen M; Hanon E; Leroux-Roels G
    Vaccine; 2010 Jan; 28(3):849-57. PubMed ID: 19835828
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Inactivated and adjuvanted whole-virion clade 2.3.4 H5N1 pre-pandemic influenza vaccine possesses broad protective efficacy against infection by heterologous clades of highly pathogenic H5N1 avian influenza virus in mice.
    Harada Y; Ninomiya-Mori A; Takahashi Y; Shirakura M; Kishida N; Kageyama T; Tada Y; Tashiro M; Odagiri T
    Vaccine; 2011 Oct; 29(46):8330-7. PubMed ID: 21911027
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Intranasal vaccination with a plant-derived H5 HA vaccine protects mice and ferrets against highly pathogenic avian influenza virus challenge.
    Major D; Chichester JA; Pathirana RD; Guilfoyle K; Shoji Y; Guzman CA; Yusibov V; Cox RJ
    Hum Vaccin Immunother; 2015; 11(5):1235-43. PubMed ID: 25714901
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Flagellin-HA vaccines protect ferrets and mice against H5N1 highly pathogenic avian influenza virus (HPAIV) infections.
    Liu G; Song L; Reiserova L; Trivedi U; Li H; Liu X; Noah D; Hou F; Weaver B; Tussey L
    Vaccine; 2012 Nov; 30(48):6833-8. PubMed ID: 23000130
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Phase I and II randomised trials of the safety and immunogenicity of a prototype adjuvanted inactivated split-virus influenza A (H5N1) vaccine in healthy adults.
    Nolan TM; Richmond PC; Skeljo MV; Pearce G; Hartel G; Formica NT; Höschler K; Bennet J; Ryan D; Papanaoum K; Basser RL; Zambon MC
    Vaccine; 2008 Aug; 26(33):4160-7. PubMed ID: 18599164
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A study of Chitosan and c-di-GMP as mucosal adjuvants for intranasal influenza H5N1 vaccine.
    Svindland SC; Pedersen GK; Pathirana RD; Bredholt G; Nøstbakken JK; Jul-Larsen Å; Guzmán CA; Montomoli E; Lapini G; Piccirella S; Jabbal-Gill I; Hinchcliffe M; Cox RJ
    Influenza Other Respir Viruses; 2013 Nov; 7(6):1181-93. PubMed ID: 23170900
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Potent adjuvant effects of novel NKT stimulatory glycolipids on hemagglutinin based DNA vaccine for H5N1 influenza virus.
    Hung JT; Tsai YC; Lin WD; Jan JT; Lin KH; Huang JR; Cheng JY; Chen MW; Wong CH; Yu AL
    Antiviral Res; 2014 Jul; 107():110-8. PubMed ID: 24786174
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Dose ranging of adjuvant and antigen in a cell culture H5N1 influenza vaccine: safety and immunogenicity of a phase 1/2 clinical trial.
    Keitel W; Groth N; Lattanzi M; Praus M; Hilbert AK; Borkowski A; Tsai TF
    Vaccine; 2010 Jan; 28(3):840-8. PubMed ID: 19835829
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Cross-protection against lethal H5N1 challenge in ferrets with an adjuvanted pandemic influenza vaccine.
    Baras B; Stittelaar KJ; Simon JH; Thoolen RJ; Mossman SP; Pistoor FH; van Amerongen G; Wettendorff MA; Hanon E; Osterhaus AD
    PLoS One; 2008 Jan; 3(1):e1401. PubMed ID: 18167560
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Safety and immunogenicity of an influenza vaccine A/H5N1 (A/Vietnam/1194/2004) when coadministered with a heat-labile enterotoxin (LT) adjuvant patch.
    Glenn GM; Thomas DN; Poffenberger KL; Flyer DC; Ellingsworth LR; Andersen BH; Frech SA
    Vaccine; 2009 Dec; 27 Suppl 6():G60-6. PubMed ID: 20006142
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A clinical trial of a whole-virus H5N1 vaccine derived from cell culture.
    Ehrlich HJ; Müller M; Oh HM; Tambyah PA; Joukhadar C; Montomoli E; Fisher D; Berezuk G; Fritsch S; Löw-Baselli A; Vartian N; Bobrovsky R; Pavlova BG; Pöllabauer EM; Kistner O; Barrett PN;
    N Engl J Med; 2008 Jun; 358(24):2573-84. PubMed ID: 18550874
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Cationic liposome-DNA complexes (CLDC) adjuvant enhances the immunogenicity and cross-protective efficacy of a pre-pandemic influenza A H5N1 vaccine in mice.
    Dong L; Liu F; Fairman J; Hong DK; Lewis DB; Monath T; Warner JF; Belser JA; Patel J; Hancock K; Katz JM; Lu X
    Vaccine; 2012 Jan; 30(2):254-64. PubMed ID: 22085545
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A cationic liposome-DNA complexes adjuvant (JVRS-100) enhances the immunogenicity and cross-protective efficacy of pre-pandemic influenza A (H5N1) vaccine in ferrets.
    Liu F; Sun X; Fairman J; Lewis DB; Katz JM; Levine M; Tumpey TM; Lu X
    Virology; 2016 May; 492():197-203. PubMed ID: 26967975
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Intranasal vaccination of recombinant H5N1 HA1 proteins fused with foldon and Fc induces strong mucosal immune responses with neutralizing activity: Implication for developing novel mucosal influenza vaccines.
    Yu F; Li Y; Guo Y; Wang L; Yang J; Zhao G; Zhou Y; Du L; Jiang S
    Hum Vaccin Immunother; 2015; 11(12):2831-8. PubMed ID: 26260706
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Stockpiled pre-pandemic H5N1 influenza virus vaccines with AS03 adjuvant provide cross-protection from H5N2 clade 2.3.4.4 virus challenge in ferrets.
    Sun X; Belser JA; Pulit-Penaloza JA; Creager HM; Guo Z; Jefferson SN; Liu F; York IA; Stevens J; Maines TR; Jernigan DB; Katz JM; Levine MZ; Tumpey TM
    Virology; 2017 Aug; 508():164-169. PubMed ID: 28554058
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Innate immunemodulator containing adjuvant formulated HA based vaccine protects mice from lethal infection of highly pathogenic avian influenza H5N1 virus.
    Lu Y; Landreth S; Liu G; Brownlie R; Gaba A; Littel-van den Hurk SVD; Gerdts V; Zhou Y
    Vaccine; 2020 Feb; 38(10):2387-2395. PubMed ID: 32014270
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.